Advertisement

Topics

OGT Attracts Over 200 Delegates to its aCGH Satellite Meeting at ESHG 2010

10:23 EDT 10 Aug 2010 | BioPortfolio

Oxford, UK – 12 July 2010. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has announced that over 200 delegates came to its satellite meeting during the recent European Human Genetics Conference (ESHG 2010) in Gothenburg, Sweden. Entitled From disease to cytogenetics research – An integrated CNV analysis platform from OGT, the delegates heard presentations from leading researchers on how OGT’s array comparative genomic hybridisation (aCGH) solutions can help advance disease and cytogenetics research.

The three presentations were: Genome-wide association study of copy number variation in 16,000 cases of eight common diseases and 3,000 shared controls, from Dr Vincent Plagnol, University College London Genetics Institute (UGI) and JDRF/WT Diabetes and Inflammation Laboratory, University of Cambridge; An International Standard Cytogenomic Array (ISCA) Consortium approach to the design, implementation and reporting of constitutional oligo array-CGH, from John A Crolla PhD FRCPath of the Wessex Regional Genetics Laboratory, Salisbury; and How to ensure the highest quality CNV data, from OGT’s Spencer Howell. More information and presentations from the meeting are now available at www.ogt.co.uk/ESHG2010.html?PR.

“We were extremely pleased with the success of the meeting”, said James Clough, OGT’s Vice President Clinical and Genomic Solutions.

“We had to increase the seating in the room to accommodate the high number of attendees, which is a testament to the quality of the speakers who are using OGT’s CytoSure™ cytogenetic arrays and Genefficiency™ genomic services in their research.”

During the workshop, OGT announced that their CytoSure Interpret Software can now seamlessly transfer aCGH aberration data directly to Cartagenia’s Bench™ constitutional cytogenetics platform, aiding cytogeneticists to accurately correlate genotypic findings with known clinical phenotypes.

To see the presentations from the OGT Satellite Meeting, go to www.ogt.co.uk/ESHG2010.html?PR.

For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk
W: www.ogt.co.uk

Notes for editors:

About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.

Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.

CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.

OGT enquiries Oxford Gene Technology - OGT
Stephen Archibald – Marketing Communications Manager
t: +44 (0)1865 856828 e: stephen.archibald@ogt.co.uk

Media enquiries Alto Marketing Limited
Neil Ravenhill – Scientific Communications Manager
t: +44 (0)1489 557672 e: neilr@alto-marketing.com
 

OGT enquiries Oxford Gene Technology - OGT Stephen Archibald – Marketing Communications Manager t: +44 (0)1865 856828 e: stephen.archibald@ogt.co.uk Media enquiries Alto Marketing Limited Neil Ravenhill – Scientific Communications Manager t: +44 (0)1489 557672 e: neilr@alto-marketing.com NEXT ARTICLE

More From BioPortfolio on "OGT Attracts Over 200 Delegates to its aCGH Satellite Meeting at ESHG 2010 "

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...